Peroxisome proliferator-activated receptor γ Pro12Ala polymorphism decrease the risk of diabetic nephropathy in type 2 diabetes: a meta analysis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Clinical and Experimental Medicine

• Publication date

  2015-05-15

• Fields of study

  Medicine

• Identifiers
  PMID 26221313PMCID PMC4509258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Pro12Ala polymorphism in peroxisome proliferator-activated receptor-γ2 gene on metabolic syndrome risk: a meta-analysis.

  2014cited by this paper
• Peroxisome proliferator activated receptor γ2 gene Pro12Ala gene polymorphism in type 2 diabetes and its relationship with diabetic nephropathy.

  2014cited by this paper
• Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: a meta-analysis.

  2013cited by this paper
• The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects

  2013cited by this paper
• Combined Effects of PPARγ Agonists and Epidermal Growth Factor Receptor Inhibitors in Human Proximal Tubule Cells

  2013cited by this paper
• The C161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARγ) is associated with risk of coronary artery disease: a meta-analysis

  2013cited by this paper
• Role of the ACE ID and PPARG P12A Polymorphisms in Genetic Susceptibility of Diabetic Nephropathy in a South Indian Population

  2013cited by this paper
• Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator–activated receptor-γ2 gene and diabetic retinopathy in Caucasians and Asians

  2012cited by this paper
• PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies.

  2011cited by this paper
• Peroxisome Proliferator–Activated Receptor γ Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes

  2010cited by this paper
• Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.

  2010cited by this paper
• The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.

  2010cited by this paper
• Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

  2010cited by this paper
• Impact of the PPAR-γ2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT

  2009cited by this paper
• Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.

  2009cited by this paper
• Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

  2009cited by this paper
• Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.

  2009cited by this paper
• From Fibrosis to Sclerosis

  2008cited by this paper
• The pathogenesis of diabetic nephropathy

  2008cited by this paper
• The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy.

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes.

  2007cited by this paper
• Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?

  2007cited by this paper
• Peroxisome proliferator-activated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients.

  2004cited by this paper
• The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.

  2003cited by this paper
• Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.

  2002cited by this paper
• Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.

  2001cited by this paper
• Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.

  2001cited by this paper
• The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature.

  2001cited by this paper

• Associations of genetic factors with vascular diabetes complications: an umbrella review

  2025cites this paper
• The impact of PPARγ and ApoE gene polymorphisms on susceptibility to diabetic kidney disease in type 2 diabetes mellitus: a meta-analysis

  2024cites this paper
• The emerging role of COX-2, 15-LOX, and PPARγ in metabolic diseases and cancer: An introduction to novel multi-target directed ligands (MTDLs).

  2020cites this paper
• Decisive evidence corroborates a null relationship between MTHFR C677T and chronic kidney disease

  2020cites this paper
• PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study—A Key for Reaching Null Association

  2020cites this paper
• Association between PPARG Pro 12 Ala polymorphism and diabetic nephropathy risk ; an updated meta-analysis of 27 studies

  2018cites this paper
• Association of MTHFR C 677 T and A 1298 C polymorphisms with the development of type 2 diabetic nephropathy and their interaction with environmental factors

  2017cites this paper